Adverse effects of concurrent carboplatin chemotherapy andradiation therapyindogs

Journal of Veterinary Internal Medicine

Volumn 23, Issue 1, 2009, Pages 24-30

  Hume, K R ^a,c   Johnson, J L ^b   Williams, L E ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c Cornell University ^*  (United States)

Author keywords

Cancer; Canine; Chemoradiotherapy; Multimodality therapy; Neoplasia; Platinum analog

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CHEMICALLY INDUCED DISORDER; DOG; DOG DISEASE; NEOPLASM; NEUTROPENIA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DOG DISEASES; DOGS; NEOPLASMS; NEUTROPENIA; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

ANIMALIA; CANIS FAMILIARIS;

EID: 61349167852     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0224.x     Document Type: Article

References (31)

1. Adelstein DJ, Saxton JP, Rybicki LA, et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: Mature results from a single institution. J Clin Oncol 2006;24:1064-1071.
2. Wilkowski R, Thoma M, Weingandt H, et al. Chemoradia-tion for ductal pancreatic carcinoma: Principles of combining chemotherapy with radiation, definition of target volume, and radiation dose. J Pancreas 2005;6:216-230.
3. Rakovitch E, Tsao M, Ung Y, et al. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: A meta-analysis. Int J Radiat Oncol Biol Phys 2004;58:196-203.
4. Solomon B, Ball DL, Richardson G, et al. Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer 2003;41:353-361.
5. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
6. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
7. Milas L, Mason KA, Liao Z, Ang KK. Chemoradiotherapy: Emerging treatment improvement strategies. Head Neck 2003;25:152-167.
8. Shehadeh NJ, Ensley JF, Kucuk O, et al. Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. Head Neck 2006;28:1090-1098.
9. Rigas JR, Lara PN. Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. Lung Cancer 2005;50:S17-S24.
10. LeBlanc AK, LaDue TA, Turrel JM, Klein MK. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004;45:466-470.
11. Nadeau M-E, Kitchell BE, Rooks RL, LaRue SM. Cobalt radiation with or without low-dose cisplatin for treatment ofcanine naso-sinus carcinomas. Vet Radiol Ultrasound 2004;45:362-367.
12. De Vos JP, Burm AGD, Focker AP, et al. Piroxicam and carboplatin as a combination treatment of canine oral non-tonsillar squamous cell carcinoma: A pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma. Vet Compar Oncol 2005;3:16-24.
13. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Compar Oncol 2005;3:73-80.
14. Langova V, Mutsaers AJ, Phillips B, Straw R. Treatment of eight dogs with nasal tumours with alternating doses of doxorubicin and carboplatin in conjunction with oral piroxicam. Aust Vet J 2004;82:676-680.
15. Slensky KA, Volk SW, Schwarz T, et al. Acute severe hemorrhage secondary to arterial invasion in a dog with thyroid carcinoma. J Am Vet Med Assoc 2003;223:649-653.
16. Williams LE, Gliatto JM, Dodge RK, et al. Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995). J Am Vet Med Assoc 2003;223:825-831.
17. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001;218:1444-1448.
18. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996;10:76-81.
19. Théon AP, Van Vechten MK, Madewell BR. Intratumoral administration of carboplatin for treatment of squamous cell carcinomas of the nasal plane in cats. Am J Vet Res 1996;57:205-210.
20. Veterinary Co-operative Oncology Group (VCOG). Veterinary co-operative oncology group common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Com-par Oncol 2004;2:194-213.
21. Page RL, McEntee MC, George SL, et al. Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med 1993;7:235-240.
22. Cotran RS, Kumar V, Collins T. Robbins Pathologic Basis of Disease, 6th ed. Philadelphia, PA: WB Saunders Company; 1999:602.
23. Fox LE. Carboplatin. J Am Anim Hosp Assoc 2000;36:13-14.
24. Fusellier M, Desfontis J-C, Madec S, et al. Influence of three anesthetic protocols on glomerular filtration rate in dogs. Am J Vet Res 2007;68:807-811.
25. Hase K, Meguro K, Nakamura T. Effects of sevoflurane anesthesia combined with epidural block on renal function in the elderly: Comparison with isoflurane. J Anesth 2000;14:53-60.
26. Reed E, Dabholkar M, Chabner BA. Platinum analogues. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Bio-therapy: Principles and Practice, 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers; 1996:357-378.
27. Hartman JC, Pagel PS, Proctor LT, et al. Influence of des-flurane, isoflurane, and halothane on regional tissue perfusion in dogs. Can J Anaesth 1992;39:877-887.
28. Ko JCH, Miyabiyashi T, Mandsager RE, et al. Renal effects of carprofen administered to healthy dogs anesthesized with prop-ofol and isoflurane. J Am Vet Med Assoc 2000;217:346-349.
29. Newell SM, Ko JC, Ginn PE, et al. Effects of three sedative protocols on glomerular filtration rate in clinically normal dogs. Am J Vet Res 1997;58:446-450.
30. Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783-1786.
31. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.